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Abstract: Today substance abuse remains one of the major problems in the world with millions of 
people abusing legal and illegal drugs. In addition, almost one-third of the world population of 6.7 
billion people may also be infected with one or more infections. Both drugs of abuse and infections are 
associated with enormous burden of social, economic and health consequences. This paper briefly 
discusses  a  few  medical  consequences  of  drugs  of  abuse  and  infections  such  as  human 
immunodeficiency virus and hepatitis C virus. Research is encouraged to study interactions between 
infections,  drugs  of  abuse,  and  underlying  pathophysiologic  and  molecular/genetic  mechanisms  of 
these interactions. 
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INTRODUCTION 
 
Today substance abuse and infections are two of 
the major problems in the world with an estimated 200 
million people abusing illegal drugs regularly
[1] and an 
estimated  one-third  of  the  world’s  population  of  6.7 
billion people living with one or more infections
2. In 
the US alone, according to the 2005 National Survey on 
Drug Use and Health
[3], about 112 million Americans 
12 years and older (46%) used at least one illicit drug 
(e.g., amphetamines, cocaine, heroin, or marijuana) in 
their  lifetime.  An  estimated  20  million  people  are 
current users of an illicit drug. Unfortunately no data 
are available on the nature and extent of drug abuse in 
India. There are an estimated 40 million people in the 
world  living  with  human  immunodeficiency  virus 
(HIV)  infection,  about  200  million  infected  with 
hepatitis C virus (HCV), 2 billion people infected with 
tuberculosis (TB) and many more millions with various 
other  bacterial  and  viral  infections
[4].  An  estimated  1 
million people infected with HIV, and 4 million people 
infected with HCV live in the US. Both infections are 
prevalent among substance abusers. Injection drug use 
(IDU)  directly  and  indirectly  accounts  for  more  than 
one-third  (36%)  of  AIDS  cases;  of  the  42,156  new 
cases  of  AIDS  reported  in  the  US  in  2000,  11,635 
(28%)  were  associated  with  injection  drug  use 
[5]. 
About  80%  to  90%  of  HIV  positive  IDUs  may  also 
infected with HCV (5). In addition to HIV and HCV, 
other  viral  and  bacterial  infections  such  as 
mycobacterial  leading  to  tuberculosis  (TB),  sexually-
transmitted infections, streptococcal and staphylococcal 
infections (leading to endocarditis) and others have all 
been reported in drug abusers
[6].   
Sociopolitical,  economic,  and  health  costs  to  the 
society  from  substance  abuse  and  infections  are 
enormous. Legal and illegal substance abuse alone costs 
the  American  society  an  estimated  one-half  a  trillion 
dollars  annually
[8],  while  diabetes  and  cancer  cost  an 
estimated  $132  billion
[9]  and  $263  billion
[10], 
respectively. Both drugs of abuse and infections such as 
HIV  and  HCV  affect  almost  every 
physiological/biochemical  system  in  the  body.  Thus, 
health  effects  may  range  between  neuropsychiatric 
complications,  anxiety  and  depressive  disorders, 
cardiovascular  complications,  impairment  of  immune 
system, metabolic/endocrine disorders (lipodystrophy), 
and hepatic failure, to name a few. Because the subject 
of health consequences of drugs of abuse and infections 
is  very  wide  and  could  not  be  covered  in  a  mini-
symposium  at  the  Drug  Abuse  and  HIV/AIDS 
conference, held for the first time in Kerala, India, a 
brief review of the current status of research on medical 
consequences  of  drug  abuse  and  infections  supported 
by the US National Institute on Drug Abuse, a part of 
the  National  Institutes  of  Health,  is  being  presented 
herein.   
Medical Consequences: In general, stimulants such 
as  cocaine  and  methamphetamine  (‘met’,  ‘speed’,  or 
‘ice’)  increase  the  heart  rate  while  constricting  the 
blood  vessels;  in  susceptible  individuals,  these  two 
actions  together  set  the  stage  for  cardiac  arrhythmias 
and  strokes
11.  Methamphetamine  also  causes  serious 
hyperthermia,  increases  wakefulness  and  physical 
activity,  creating  the  potential  for  a  combination  of 
activity and overheating that leads to convulsions and 
dangerous,  sometimes  lethal  elevation  of  body 
temperature
[11]. Cocaine use decreases the blood flow to 
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the  brain,  increases  the  heart  rate,  and  elevates  the 
blood  components  that  promote  clotting—effects  that 
can  lead  to  stroke  or  heart  attack  even  in  those  not 
otherwise  at  risk  for  these  serious  cardiovascular 
events
[11].  NIDA-funded  research  also  shows  that 
chronic cocaine use is associated with left ventricular 
dysfunction
[12]  and  increased  calcium  deposits  in  the 
coronaries
[13] of HIV infected African-Americans, and 
that its  use  may also  facilitate the entry of HIV into 
brain cells
[14], possibly leading to HIV encephalopathy. 
The  club  drug  methylene-dioxy-methamphetamine 
(MDMA), also known as ‘ecstasy’, which many users 
mistakenly  believe  to  be  safe,  may  cause  malignant 
hyperthermia, permanent kidney damage, and death. In 
non-human  primate  studies,  MDMA  also  damages 
serotonin nerve fibers in the brain. Heroin can cause a 
life-threatening  kidney  renal  condition  called  focal 
glomerulosclerosis
[15]. Opiate (heroin) use is associated 
with  consequences  ranging  from  nausea  and 
constipation  to  renal,  dental,  and  orofacial 
complications.  PCP  (phencyclidine,  or  ‘angel  dust’) 
decreases heart rate and blood pressure, triggers violent 
aggression, and may trigger muscle contractions strong 
enough to break a bone
[11]. Marijuana, the most abused 
illicit drug in the world and often perceived by many as 
an  innocuous  drug,  is  associated  with  consequences 
ranging from memory, cognitive and motor problems in 
young and adult individuals to possible lung cancer in 
chronic marijuana smokers, although the latter have not 
been  confirmed.  The  NIDA-published  special 
supplement reviewed the most up-to-date research on 
clinical consequences of marijuana
[16].  Injecting drug 
use and drug use associated impulsive sexual activity 
further  promotes  acquisition  and  transmission  of 
sexually-transmitted  and  blood-borne  infections 
including  life-threatening  endocarditis,  viral  hepatitis, 
HIV/AIDS and STDs.   
 
Human  Immunodeficiency  Virus  (HIV):  HIV,  a 
blood-borne  retrovirus  that  infects  CD4  T-cell 
lymphocytes  and  macrophages,  causes  profound 
immunosuppression that eventually develops into full-
blown  AIDS.  HIV  infection  results  into  flu-like 
syndrome  consisting  of  fever,  fatigue,  pharyngitis, 
decreased  CD4  T-cell  lymphocytes,  increased  viral 
load,  and  finally  progression  to  AIDS,  the  latter 
depending on  factors such as the  use of illicit drugs, 
opportunistic  infections  (OI)  prophylaxis,  and 
antiretroviral therapy. It may be noted that in about 5% 
of  the  individuals,  the  disease  does  not  progress  to 
AIDS. These individuals are known as long-term non-
progressors and have a low  viral load burden, strong 
virus-specific  immune  responses,  and  moderate  viral 
attenuation
[17]. Since the virus may infect almost every 
organ, the effects of HIV infection may also range from 
immunosuppression  to  wasting  and  other 
metabolic/endocrine  disorders,  cardiomyopathy, 
nephropathy,  neuroAIDS,  and  many  other  health 
consequences.  The  course  of  HIV  infection  and  the 
development  of  AIDS  are  further  complicated  by 
metabolic and endocrine abnormalities secondary to the 
direct toxic effects of HIV, other OIs such as HCV, TB, 
STIs,  neoplasms,  and  complications  of  drugs  used 
during treatment.     
 
Hepatitis C Virus: Hepatitis C virus is another blood-
borne  pathogen  that  is  easily  transmitted  through 
contaminated  drug  injection  paraphernalia. 
Approximately 40% of chronic liver disease is related 
to HCV infection, making it the most common cause of 
chronic  liver  disease  and  the  major  reason  for  liver 
transplantation  performed  in  the  US.  An  estimated 
8,000 to 10,000 persons with HCV-related liver cancer 
may  die  each  year
[18].    Because  HIV  and  HCV  have 
common  transmission  pathways,  coinfection  is  quite 
frequent,  with  prevalence  as  high  as  90%  of  HIV-
infected  IDUs  also  infected  with  HCV  in  some 
countries  in  Central,  South,  and  Southeast
  Asia  and 
Eastern  Europe
[19,  20,  21],  50  to  75%  in  countries  in 
Southeast
 Asia
[22]; 33% in St. Petersburg, Russia
23; and 
50 to 55% in Australia
[24]. Recent reports from India 
show  that  there  are  an  estimated  5.6  million  people 
living with HIV infection
[25]; no numbers are available 
on co-infections with HIV/HCV. 
During the acute phase of HCV infection, which is 
difficult  to  diagnose  and  which  may  last  about  six 
weeks,  symptoms  may  include  malaise,  nausea,  right 
upper quadrant pain, and jaundice. About 75 to 85% of 
these patients may become chronically infected. During 
the  chronic  phase  of  HCV  infection,  which  may  last 
several  decades,  symptoms  may  include  nausea, 
anorexia, myalgia, and arthralgia, with fatigue being the 
most common complaint
[26]. Alcohol use and advanced 
age  accelerate  the  disease  progression  of  HCV 
infection, especially among men. Approximately 20% 
of  these  chronic  patients  will  develop  liver  cirrhosis 
within  20  years,  and  1  to  5%  of  them  will  die  from 
HCV-related  liver  cancer.  HCV  infection  is  also 
associated  with  the  development  of  diabetes  mellitus 
among  IDUs
[27].  Dual  infections  with  HIV  and  HCV 
also  occur  from  common  routes  of  transmission  and 
these individuals are at risk of developing chronic liver 
inflammation  and  hepatic  cancer  or  liver  failure 
requiring transplantation. Hepatic injury seems to occur 
in  dual  infections  through  the  induction  of  a  novel 
signaling  pathway,  that  is  cooperatively  activated  by 
specialized protein molecules, known as HCV E2 and 
HIV  gp120,  thereby  providing  a  rationale  for 
therapeutic  interventions
[28]  .  NIDA  supports  a  wide 
spectrum of research on epidemiology, natural history, 
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underlying  pathogenesis,  prevention  and  treatment  of 
HIV/HCV co-infections among drug abusers.    
 
Tuberculosis:  Among  all  the  infectious  diseases  that 
affect  humans,  TB  remains  the  deadliest  contagious 
disease  caused  by  Mycobacterium  tuberculosis,  a 
pathogenic  bacterium  that  establishes  its  infection 
mainly in the lungs. An estimated 2 billion people in 
the world are living with TB and an estimated 2 million 
die each year. India has the largest number of TB cases 
with an estimated 1000 people dying each day
[29]. In the 
United States, a total of 13,767 tuberculosis (TB) cases 
(4.6  per  100,000  population)  were  reported  in  2006 
with  rates  of  TB  incidence  declining  from  7.3%  per 
year  during  1993--2000  to  3.8%  during  2000--2006. 
Progression of TB is accelerated by a number of factors 
such  as  co-occurring  infections,  e.g.,  HIV,  drugs  of 
abuse, poor nutrition, and many others. HIV contributes 
to  the  TB  pandemic  because  HIV-induced  immune 
suppression  increases  the  likelihood  of  rapid 
progression  from  primary  TB  infection  to  active  TB 
disease. But from 2005 to 2006, the percentage of TB 
cases  with  HIV  infection  has  also  decreased  from 
13.0% to 12.4% 
[30]. Drug users are at particularly high 
risk of TB infection with reported high rates of active 
TB  among  drug  users
[31,  32].  TB  infection  can  be 
effectively  treated  with  currently  available  drugs 
including  isoniazid,  rifampin,  streptomycin, 
ethambutol, pyrazinamide, ciprofloxacin, and ofloxacin. 
On the other hand, although the rates of TB incidence 
have declined in the US and elsewhere, the emergence 
of multi-drug resistant strain of mycobacterium (MDR) 
and  extremely  drug  resistant  (XDR)  strain  of  the 
bacterium is of major concern. A total of 124 cases of 
multidrug-resistant  TB  (MDR  TB)  were  reported  in 
2005,  mostly  in  foreign-born  individuals.  Thus, 
vigorous efforts are underway to find better diagnostic 
tests/tools and to design/develop effective intervention, 
prevention and treatment modalities. 
Nutrition also might play an important role in HIV 
disease  progression.  Research  suggests  that  drug 
abusers with inadequate nutrition, particularly with sub-
optimal  levels  of  anti-oxidant  micronutrients  such  as 
selenium and zinc, may be at high risk of mortality if 
they are also co-infected with HIV
[33]. NIDA-supported 
clinical  trials  are  in  progress  to  determine  if 
supplementation  with  selenium,  zinc,  and  other  anti-
oxidant micronutrients would slow the progression of 
HIV/AIDS disease. Daily supplementation with 200 ug 
of  selenium  increases  the  CD4  T  cell  lymphocyte 
counts  and  decreases  the  viral  load  in  HIV-infected 
patients
[34].  This  type  of  research  would  have 
worldwide  implications,  such  that,  in  underdeveloped 
countries  where  poor  people  cannot  afford  expensive 
antiretroviral  therapy,  they  could  benefit  from 
inexpensive  treatment  modality  to  slow  disease 
progression and improve the quality of life. 
Both  viral  infections  of  Hepatitis  C  and  HIV 
continue  to  spread  in  an  epidemic  fashion  among 
vulnerable  populations,  including  those  with  mental 
illness  and  drug  addiction.    Drug  abuse  remains  the 
major vector in the acquisition and transmission of both 
infections  with  serious  consequences
[35]  including 
psychiatric disorders that in turn may further maintain 
Hepatitis C epidemic.  Major depression, severe mental 
illness,  and  personality  disorders  lead  to  high  risk 
behaviors for Hepatitis C, and yet these disorders may 
be made worse by Hepatitis C and the medications used 
to  treat  it
[36].  Major  depression  is  a  common  co-
morbidity in patients with Hepatitis C infection
[37].  
Hepatitis C patients also have poorer outcomes if 
they are ongoing drug users
[26].  Alcohol is risk factor 
for Hepatitis C infection, probably through the indirect 
mechanisms, but it is also associated with more rapid 
progression of HCV and more frequent development of 
liver  cancer
[38].    Despite  these  ominous  problems, 
patients  with  substance  use  disorders  can  be 
successfully  treated  for  HIV  and  Hepatitis  C  if  the 
clinical resources needed for treatment are provided
[39-
41].  
Mental  illness  including  anxiety  disorders,  major 
depression  and  bipolar  disorder  are  associated  with 
substance use, increased high risk sexual behavior, and 
with  other  self  destructive  behaviors
[42].    Depression 
may also increase the risk of acquiring HIV and HCV 
infections  and  may  interfere  with  treatment.    On  the 
other  hand,  depression  may  also  be  caused  by 
antiretroviral  medications  such  as  efavirenz
[43]  and 
interferon  used  in  the  treatment  of  HCV  infection. 
Although ribavirin, also used in the treatment of HCV 
infection,  may  worsen  depression,  interferon  is 
associated with severe CNS side effects such as frank 
psychosis,  which  may  persist  after  discontinuation. 
Other  common  symptoms  are:  apathy,  fatigue, 
irritability,  sleep  disturbance  (both  hypersomnia  and 
insomnia),  confusion,  inattention,  anorexia,  sexual 
dysfunction,  and  suicidal  feelings
[44].  Treatment  with 
antidepressants is effective but does not favor any one 
class of medications.  Thus, treatment agents need to be 
developed that are safe (devoid of severe side effects) 
and effective against single or dual infections of HIV 
and/or HCV in drug abusing populations.  
 
Drug  Interactions:  Pharmacokinetic  and 
pharmacodynamic  interactions  between  medications 
used in the treatment of infections and addiction should 
be considered when designing treatment protocols for 
drug addicts. Despite the large number of drug abusers 
with HIV disease, HAART is frequently underutilized 
in  this  population  because  of  the  difficulties 
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experienced  in  obtaining  adherence  adequate  to 
maintain  viral  suppression
[45-48].    Provision  of  drug 
abuse treatment is often a key component to successful 
treatment of HIV disease in this population. Multiple 
studies  have  shown  that  drug  interactions  between 
antiretrovirals and other medications having effects on 
cytochrome  p450  enzymes  can  lead  to  altered 
therapeutic  profiles,  toxicities  and  side  effects  with 
drugs used for the treatment of HIV
[49]. This, in turn, 
may  decrease  adherence  to  medical  treatment  for 
HIV/AIDS
[50]  leading  to  lack  of  efficacy  of  HIV 
treatment, development of viral resistance to currently 
available  therapies,  and  increased  illicit  drug  abuse. 
Because opioid pharmacotherapies are the treatment of 
choice for opioid-addicted individuals with HIV/AIDS, 
it  is  essential  that  clinicians  have  a  thorough 
understanding  of  possible  drug  interactions  between 
opioids, specifically methadone and buprenorphine, and 
antiretroviral therapies in order to enhance the clinical 
care of drug users with HIV/AIDS.   
The  earlier  studies  showed  interactions  between 
methadone and antiretrovirals. For example, the plasma 
levels of zidovudine increased by 41% when used in the 
treatment of AIDS in methadone maintained patients
[51] 
but not in buprenorphine maintained patients
[52].  On the 
other hand, patients treated with protease inhibitors like 
lopinavir/ritonavir  or  non-nucleoside  reverse 
transcriptase  inhibitor  (NNRTI)  efavirenz,  the  plasma 
levels  of  methadone  decreased  resulting  in  opiate 
withdrawal
[53-55].  By  contrast,  no  clinically  significant 
interactions  occurred  between  ARVs  and 
buprenorphine
[53,54]. Data show that now buprenorphine 
may offer an alternative opioid therapy that could help 
to  improve  adherence  to  antiretroviral  medications 
prescribed for the treatment of HIV disease in opioid-
dependent patients.   
 
New  Pharmacotherapeutics  on  the  Horizon:  Since 
the discovery of the first case of HIV, many effective 
medications  including  highly  active  antiretroviral 
therapy (HAART) and the newest drug, Fusion, have 
been developed for the treatment of HIV/AIDS. On the 
other hand, only pegylated interferon alfa and ribavirin 
are available for the treatment of hepatitis C infection. 
However, new drug therapies to treat hepatitis C (HCV) 
and HIV infection are being developed with improved 
understanding of the molecular structures of the viruses 
themselves,  the  pathogenesis  of  infection  and  the 
specific  immune  responses  needed  to  eradicate  or 
control these infections. Interferon and ribavirin  based 
therapies  will  continue  to  be  a  component  of  HCV 
therapy for the near future combined with other novel 
compounds  directed  at  targets  of  viral  replication, 
immunomodulation  or  cell  entry.  The  goals  of  anti-
HCV  therapy  are  viral  eradication  for  various 
genotypes,  prevention  of  hepatic  morbidity  such  as 
hepatocellular  carcinoma  and  cirrhosis.    Future 
antiretroviral therapies for HIV will include agents that 
focus on new classes of inhibitors of viral replication 
and  cell  binding.  The  new  treatment  choices  in  HIV 
will  need  to  ensure  effective  and  durable  viral 
suppression  especially  against  highly  resistant  virus 
strains, regimen tolerability and improved toxicity  
 
Targets for Hepatitis C Infection: A number of new 
agents  are  in  development  for  the  treatment  of  HCV 
infection since the goals of ARV therapy are to limit 
viral  replication,  prevent  new  infection,  and  enhance 
clearance of infected cells. Currently, drug candidates 
in various stages of development are: (i) A derivative of 
interferon, such as albuferon
[56,  57], and derivatives of 
ribavirin  such as  viramadine or taibivirin); (ii) Drugs 
directed  against  components  of  HCV  genome  (e.g., 
protease inhibitors such as telaprevir or VX-950; SCH 
503034;  nucleoside  HCV  RNA  polymerase  inhibitors 
such  as  valopicitabine  (NM283),  R1626  and  HCV-
796); and (iii) Immune modulators including vaccines 
(such  as  isatoribine,  a  Toll-like  receptor  agonist  that 
stimulates the natural immune response to a pathogen 
such as hepatitis C; and CPG 10101, a TLR9 receptor 
agonist  that  acts  as  an  antiviral  and  Th1  immune 
enhancer
[58, 59]. 
 
Targets for HIV Infection: Currently there are at least 
26 FDA approved drugs for the treatment of HIV/AIDS 
and these belong to four classes of drugs and include: 
nucleoside  reverse  transcriptase  inhibitors  (NRTI’s), 
non-nucleoside  reverse  transcriptase  inhibitors 
(NNRTIs),  protease  inhibitors  (PIs)  and  one  fusion 
inhibitor (FI). New formulations of drugs are available 
to  reduce  pill  burden  such  as  a  single  pill  daily 
(emcitritabine/tenofovir/efavirenz) or newer agents in a 
class  that  may  suppress  resistant  virus  strains  e.g. 
darunavir, a PI with excellent virologic activity against 
HIV with multiple resistance mutations
[60]. 
Newer therapeutic agents in development include 
the  following:  (1)  Entry  inhibitors  such  as  CXCR4 
(AMD 070) or the CCR5 receptor blockers (maraviroc 
and  vicriviroc);  (2)  integrase  inhibitors  such  as  MK-
0518 and GS-9137 and (3) maturation inhibitor such as 
PA-457
61 are in various stages of development.  These 
new  agents,  singly  or  in  combination  to  overcome 
acquired resistance development, may provide options 
for both naïve and treatment experienced HIV infected 
patients.  In  the  absence  of  preventive  or  therapeutic 
vaccines  for  hepatitis  C  or  HIV,  the  intersections  of 
human  behavior,  genetics  and  pharmacology  will 
provide  ongoing  challenges  to  the  management  of 
infected persons. 
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CONCLUSION  
 
In  summary,  both  drug  abuse  and  single  or  dual 
infections of HIV and HCV are associated with a wide 
variety  of  serious  medical  and  health  consequences. 
Although treatment of drug addiction and infections of 
HIV  and/or  HCV  is  complex,  it  is  achievable  with 
integrated programs of health care for dually infected 
drug  addicts.  The  problem  of  drug  interactions  that 
appeared  between  HIV  antiretrovirals  and  methadone 
seems  to  be  less  with  the  newly  approved 
buprenorphine.  Future  research  will  show  whether 
similar  interactions  would  occur  between 
buprenorphine or methadone and newer drugs that are 
being developed for the treatment of HIV and HCV. It 
is  also  anticipated  that  the  newer  antiretroviral 
medications  would  have  lesser  neuropsychiatric 
complications or pharmacokinetic interactions.   
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